Maxim Group analyst Jason McCarthy maintained a Buy rating on Achieve Life Sciences (ACHV – Research Report) yesterday and set a price target of $8.00. The company’s shares opened today at $2.81.
According to TipRanks, McCarthy is an analyst with an average return of -39.2% and a 13.37% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Daré Bioscience, Lineage Therap, and SELLAS Life Sciences Group.
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $21.00, implying a 647.33% upside from current levels. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.60 and a one-year low of $2.00. Currently, Achieve Life Sciences has an average volume of 72.76K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- Achieve Life Sciences announces last subject dosed in Phase 3 ORCA-3 trial
- Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
- Achieve Life Sciences granted U.S. patent for cytisinicline formulation
- Achieve Life Sciences reports Q3 EPS ($1.35), consensus ($1.13)
